By Siddhi Mahatole Feb 17 (Reuters) - Disc Medicine said on Tuesday it will pursue a traditional U.S. approval pathway for ...

The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through ...

FDA vouchers are normally a coveted prize for biopharma companies, but a surprise rejection for Disc Medicine’s rare disease drug has biopharma reconsidering.

The FDA in October 2025 granted bitopertin its Commissioner’s National Priority Voucher but after a shortened review time has decided the data did not support regulatory approval for treating ...

In 2025, WinXDVD solidified its position as a primary authority in the digital asset preservation market. The brand has now surpassed 215 million total user downloads across 200+ countries and ...

When the first SuperSix was released in 2007, it was Cannondale’s first full carbon fibre bike. The bike replaced the ...

Disc Medicine received a Complete Response Letter (CRL) from FDA for its New Drug Application (NDA) for bitopertin as a treatment for erythropoietic protoporphyria (EPP), delaying a potential ...

Detailed price information for Disc Medicine Inc (IRON-Q) from The Globe and Mail including charting and trades.

For competitive racers and weekend enthusiasts alike, an ultralight bicycle wheelset is often the most transformative upgrade ...

FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use of ...